Le Lézard
Classified in: Health
Subjects: PDT, PET

Woof Introduces Innovative Line of Wellness-Focused Pupsicle Pops & Soft Chews


Woof's Breakthrough Product Line Offers Playful Solutions Tailored for Dogs' Health and Vitality

DENVER, April 17, 2024 /PRNewswire/ -- Woof, the award winning brand behind The Pupsicle, is proud to announce its newest (and tastiest) innovation yet - Wellness Pops. Reimagining the way pets access nutrition, Wellness Pops imbue essential nutrients into Pupsicle refill treats, delivering functional health benefits through long-lasting play that dogs love.

Woof's Wellness Line includes an array of products tailored to specific needs, like Joint Health, Allergy Support, Calming Support, and All-in-1 Nutrition. In addition, the line features corresponding Soft Chew supplements that make it easy to craft a consistent wellness routine for your dog.

"We want to make wellness easier for dogs & their parents," says Daniel Haarburger, CEO and Founder at Woof. "Life gets busy, and it's easy to push nutrition aside. With our Wellness line, we're making nutrition convenient by merging it with the long-lasting Pupsicle play that dogs (and their owners) love."

Woof's new Daily Wellness line features a mix of Pupsicle Refill Pops and Soft Chew supplements, including:

Woof invites dog owners to experience the joy of wellness with their furry companions through this first-to-market Wellness line. For more information and to purchase the new products, visit mywoof.com/pages/wellness.

About Woof:
Woof is redefining dog care by merging long-lasting play and functional wellness for dogs. With a commitment to quality, sustainability, and thoughtful design, Woof helps dogs enjoy safer, healthier play and their owners enjoy the peace of mind that comes with it. To learn more, visit mywoof.com or follow on Instagram.

SOURCE Woof


These press releases may also interest you

at 04:52
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled,...

at 04:09
A news report from China Daily: The 2024 ZGC Forum in Beijing showcased a wide range of latest technological innovations. The event ran from April 25 to 29 and comprised 128 activities, including forums and conferences, technology exchanges,...

at 04:05
Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , disclosed today that under the...

at 03:38
Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months. January ? March...

at 03:05
The European Academy of Allergy and Clinical...

at 03:00
BioWorldtm published by  Clarivate Plc , a leading global provider of transformative intelligence, explores the growing investment in CAR T therapy development in mainland China in a new series titled "China's CAR T market comes of age." The report...



News published on and distributed by: